Podcast: Conserving a martyred village, abortion drug shortages, identifying HIV

<p>The village of Oradour-sur-Glane continues to memorialise the massacre of 643 of its inhabitants by the Nazis in 1944. Are shortages of an abortion drug in France linked to the anti-abortion movement in the United States? And the French doctor who helped identify HIV in the early days of the Aids epidemic.</p> <p>On 10 June 1944, Nazi troops<em> </em>entered the buccolic village of Oradour-sur-Glane in central France and massacred 643 men, women and children. They then burnt it to the ground. Later that year, General <span><span><span><span><span><span>Charles de Gaulle declared Oradour a ‘<a href="https://www.oradour.org/lieu-de-memoire">martyred village</a>’, giving instructions that its state of destruction should be conserved as a permanent reminder of Nazi barbarity. </span></span></span></span></span></span><span><span><span><span><span><span>Babeth Robert, the head of the village's <a href="https://www.oradour.org/">remembrance centre</a>, talks about life among the ruined remains. <span>Benoit Sadry, the head of the <a href="https://www.anfmog.fr/accueil.html">association</a> of families of victims of the massacre, reflects on family history and the need to conserve the site against the ravages of time. </span></span></span></span></span></span></span>(Listen @0')</p><p><span><span><span><span><span><span>As the US Supreme Court in April was considering a case to de-authorise the use of mifepristone – one of two drugs used in medication abortions – many abortion providers in France were experiencing a shortage of misoprostol, the other drug. Isabelle Louis of the <a href="https://www.planning-familial.org/fr/le-planning-familial-de-paris-75">Planning Familiale</a>, which provides abortions in the Paris area, talks about the shortage and its impact on patients. <a href="https://twitter.com/londeixp">Pauline Londeix</a>, of the </span></span></span></span></span></span><span><span><span><span><span><span><span><a href="https://otmeds.org/">Observatory for transparency in drug policies</a>,</span> says th